References
- Fb T, Brasso K, Klotz LH, et al. Active surveillance for clinically localized prostate cancer–A systematic review. J Surg Oncol. 2014;109(8):830–835.
- MA D, Cowan JE, Simko J, et al. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int. 2011;107(8):1232–1237.
- Peterson S, Basak R, Moon DH, et al. Population-based cohort of prostate cancer patients on active surveillance (AS): guideline adherence, conversion to treatment and decisional regret. J clin oncol. 2019;37(15_suppl):6512.
- GS K, Lockwood G, Evans A, et al. Clinical predictors of gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer. 2007;109(12):2432–2438.
- Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis. Prostate. 2019;79(8):880–895.
- MB D, Pilarski R, Berry M, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Canc Netw. 2017;15(1):9–20.
- Dk O, Davidson KW, Krist AH, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer. JAMA. 2019;322(7):652.
- MR S, Sandhu SK, Kelly WK, et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD. J clin oncol. 2019;37(7_suppl):202.
- Mateo J, Porta N, McGovern UB, et al. TOPARP-B: a phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations. J clin oncol. 2019;37(15_suppl):5005.
- Bill-Axelson A, Holmberg L, Filén F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100(16):1144–1154.
- Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in prostate cancer — 29-year follow-up. N Engl J Med. 2018;379(24):2319–2329.
- Gallagher D, Bao M, Gaudet M, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010;16(7):2115–2121.
- Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977–1984.
- Randazzo M, Müller A, Carlsson S, et al. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss european randomised study of screening for prostate cancer (ERSPC, Aarau). BJU Int. 2016;117(4):576–583.
- SG S, Sestak I, Forster A, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol. 2016;27(4):575–590.
- Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with Abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19(7):975–986.
- Jh H, DA O, SD P, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010;304(21):2373–2380.
- Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9.
- Sd G, Wordsworth S, Payne K. Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med. 2008;10(9):648–654.
- Jr B, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the “DEALE”). I. Validation of the method. Am J Med. 1982;73(6):883–888.
- Arias E, Xu J, Kochanek KD National Vital Statistics Reports Volume 68, Number 4 May 7, 2019 United StatesLife Tabales, 2016. Vol 68; 2019. https://www.cdc.gov/nchs/products/index.htm. Accessed 2020 Oct 13
- Consumer Price Index Factsheets: U.S. Bureau of Labor Statistics. https://www.bls.gov/cpi/factsheets/home.htm. Accessed 2020 Oct 13
- VA National Acquisition Center Contract Catalog Search Tool. https://www.vendorportal.ecms.va.gov/NAC/Pharma/List?cboContractNumbers=&cboContractorNames=&txtCriteria1=olaparib&TxtNDC=&txtPackage=&cboVAClass=&Sort=1&search=Search. Accessed 2020 Oct 13
- SY W, Wang R, Yu JB, et al. Understanding regional variation in medicare expenditures for initial episodes of prostate cancer care. Med Care. 2014;52(8):680–687.
- Mr C, Ramakrishna NR, Duff SB, et al. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013;111(3):437–450.
- Scott RD The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention. https://www.cdc.gov/hai/pdfs/hai/scott_costpaper.pdf accessed 2020 Oct 12
- Ij K, M-l E-B, Borsboom GJJM, et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer. 2005;116(2):291–296.
- EQ W, Mulani P, Farrell MH, et al. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value Health. 2007;10(5):408–414.
- Skaltsa K, Longworth L, Ivanescu C, et al. Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer. Value Health. 2014;17(2):238–244.
- Prostate Cancer: Statistics Cancer.Net. https://www.cancer.net/cancer-types/prostate-cancer/statistics Accessed 2020 Nov 3
- Prostate Cancer - Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/prost.html. Accessed 2020 Nov 3
- Gd S, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
- Consumer Price Index Factsheets: U.S. Bureau of Labor Statistics. https://www.bls.gov/cpi/factsheets/home.htm. Accessed 2020 Nov 3
- Singh S, Nosyk B, Sun H, et al. Value of Information of a clinical prediction rule: informing the efficient use of healthcare and health research resources. Int J Technol Assess Health Care. 2008;24(1):112–119.
- HW T, Strong M, Gordon LG, et al. Efficient value of information calculation using a nonparametric regression approach: an applied perspective. Value Health. 2016;19(4):505–509.
- Lao C, Edlin R, Rouse P, et al. The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer. BMC Cancer. 2017;17(1):1.
- Fee Schedules - General Information - Centers for Medicare & Medicaid Services. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/FeeScheduleGenInfo/index.html. Accessed 2020 Nov 3
- MY B, Lauer JA, de Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925–930.
- Dale W, Basu A, Elstein A, et al. Predicting utility ratings for joint health states from single health states in prostate cancer: empirical testing of 3 alternative theories. Med Decis Mak. 2008;28(1):102–112.
- Manchanda R, Burnell M, Loggenberg K, et al. Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. J Med Genet. 2016;53(7):472–480.
- IBM Micromedex RED BOOK - Overview - United States. https://www.ibm.com/us-en/marketplace/micromedex-red-book. Accessed 2020 Oct 13
- Rashid N, Koh HA, Baca HC, et al. Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. Breast Cancer (Dove Med Press). 2016;8:173–181.
- Tong S, Amand C, Kieffer A, et al. Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008-2014 11 medical and health sciences 1117 public health and health services. BMC Health Serv Res. 2018;18(1):1.
- KA B, Woolley JM, Mu F, et al. The Cost of Hyperkalemia in the United States. Kidney Int Rep. 2018;3(2):385–393.
- Pignone M, Earnshaw S, Pletcher MJ, et al. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Internal Med. 2007;167(3):290–295.
- Kr Y, Davis WW, Lamont EB, et al. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007;99(1):14–23.
- National Institute for Health and Clinical Excellence. Discounting of health benefits in special circumstances. Available from: https://www.nice.org.uk/guidance/ta235/resources/osteosarcoma-mifamurtide-discounting-of-health-benefits-in-special-circumstances2 Accessed 2021 Sep 19
- Hb C, Helfand B, Mamawala M, et al. Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer. Eur Urol. 2019 May;75(5):743–749. Epub 2018 Oct 8. PMID: 30309687; PMCID: PMC6699614.